NCT02303171View on ClinicalTrials.gov

Use of Warfarin After the First Trimester in Pregnant Women With APS

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Recurrent MiscarriageAntiphospholipid Syndrome
Interventions
DRUG

Enoxaparin

Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)

DRUG

Warfarin

Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy

Trial Locations (2)

35111

RECRUITING

Obstetrics and Gynecology Department in Mansoura University Hospital, Al Mansurah

Unknown

RECRUITING

Private practice settings, Al Mansurah

All Listed Sponsors
lead

Mohamed Sayed Abdelhafez

OTHER